1. Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece;
2. Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece;
3. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden;
4. Biocrystallography Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy;
5. Hematology and Oncology, Department of Internal Medicine, University Hospital Brno, Brno, Czech Republic;
6. Faculty of Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic;
7. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden;
8. Hematopoietic Cell Transplantation Unit, Department of Hematology, G. Papanikolaou Hospital, Thessaloniki, Greece;
9. Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden;
10. Department of Hematology, Hôpital Pitié-Salpêtrière and Sorbonne University, Paris, France;
11. Medical Oncology, Università Vita-Salute San Raffaele, Milan, Italy; and
12. Strategic Research Program on CLL, B Cell Neoplasia Unit, Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy